CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings

2.1.1.Top impacting factors
2.1.2.Top investment pockets

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Porter's five forces analysis

3.2.1.Bargaining power of suppliers
3.2.2.Bargaining power of buyers
3.2.3.Threat of substitution
3.2.4.Threat of new entrants
3.2.5.Intensity of competitive rivalry

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Increase in demand for functional food in developing nations
3.3.1.2.Rise in consumption of sports and energy drinks.
3.3.1.3.Increase in purchasing power and changes in lifestyle and food habits.
3.3.1.4.Increasing demand for nutraceuticals to supplement regular diet

3.3.2.Restraints

3.3.2.1.Counterfeit and low quality products affecting the market.
3.3.2.2.Challenges related to manufacturing technology and processing.

3.3.3.Opportunities

3.3.3.1.Greater demands for herbal nutraceutical products can help the market grow.
3.3.3.2.New format of intakes of nutraceuticals

3.4.Covid-19 analysis

3.4.1.Overview:
3.4.2.Impact on food and beverage sector:
3.4.3.Impact on nutraceuticals market:

3.5.Supply chain analysis
3.6.Consumer survey analysis

CHAPTER 4:NUTRACEUTICALS MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast, by Type

4.2.Functional beverages

4.2.1.Key market trends, growth factors, and opportunities

4.2.1.1.Energy and Sports Drinks-
4.2.1.2.Functional Juices –
4.2.1.3.Others

4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Functional food

4.3.1.Key market trends, growth factors, and opportunities

4.3.1.1.Probiotics-
4.3.1.2.Minerals-
4.3.1.3.Proteins & Amino Acids-
4.3.1.4.Prebiotics, & Dietary Fibers-
4.3.1.5.Vitamins-
4.3.1.6.Others-

4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Dietary supplements

4.4.1.Key market trends, growth factors, and opportunities

4.4.1.1.Vitamins-
4.4.1.2.Botanicals-
4.4.1.3.Minerals-
4.4.1.4.Proteins & Amino Acids-
4.4.1.5.Fibers & Specialty Carbohydrates-
4.4.1.6.Omega Fatty Acids-
4.4.1.7.Others-

4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

CHAPTER 5:NUTRACEUTICALS MARKET, BY FORM

5.1.Overview

5.1.1.Market size and forecast, by Form

5.2.Capsule and tablets

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Liquid

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Powder

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Others

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country

CHAPTER 6:NUTRACEUTICALS MARKET, BY SALES CHANNEL

6.1.Overview

6.1.1.Market size and forecast, by Sales channel

6.2.Hypermarket/Supermarket

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country

6.3.Specialty stores

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country

6.4.Pharmacy

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country

6.5.Online channels

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market analysis, by country

CHAPTER 7:NUTRACEUTICALS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast, by region

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by Type
7.2.3.Market size and forecast, by Form
7.2.4.Market size and forecast, by Sales channel
7.2.5.Market analysis, by Country

7.2.5.1.U.S.

7.2.5.1.1.Market size and forecast, by Type
7.2.5.1.2.Market size and forecast, by Form
7.2.5.1.3.Market size and forecast, by Sales channel

7.2.5.2.Canada

7.2.5.2.1.Market size and forecast, by Type
7.2.5.2.2.Market size and forecast, by Form
7.2.5.2.3.Market size and forecast, by Sales channel

7.2.5.3.Mexico

7.2.5.3.1.Market size and forecast, by Type
7.2.5.3.2.Market size and forecast, by Form
7.2.5.3.3.Market size and forecast, by Sales channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by Type
7.3.3.Market size and forecast, by Form
7.3.4.Market size and forecast, by Sales channel
7.3.5.Market analysis, by Country

7.3.5.1.UK

7.3.5.1.1.Market size and forecast, by Type
7.3.5.1.2.Market size and forecast, by Form
7.3.5.1.3.Market size and forecast, by Sales channel

7.3.5.2.Germany

7.3.5.2.1.Market size and forecast, by Type
7.3.5.2.2.Market size and forecast, by Form
7.3.5.2.3.Market size and forecast, by Sales channel

7.3.5.3.Italy

7.3.5.3.1.Market size and forecast, by Type
7.3.5.3.2.Market size and forecast, by Form
7.3.5.3.3.Market size and forecast, by Sales channel

7.3.5.4.France

7.3.5.4.1.Market size and forecast, by Type
7.3.5.4.2.Market size and forecast, by Form
7.3.5.4.3.Market size and forecast, by Sales channel

7.3.5.5.Spain

7.3.5.5.1.Market size and forecast, by Type
7.3.5.5.2.Market size and forecast, by Form
7.3.5.5.3.Market size and forecast, by Sales channel

7.3.5.6.Rest of Europe

7.3.5.6.1.Market size and forecast, by Type
7.3.5.6.2.Market size and forecast, by Form
7.3.5.6.3.Market size and forecast, by Sales channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by Type
7.4.3.Market size and forecast, by Form
7.4.4.Market size and forecast, by Sales channel
7.4.5.Market analysis, by country

7.4.5.1.China

7.4.5.1.1.Market size and forecast, by Type
7.4.5.1.2.Market size and forecast, by Form
7.4.5.1.3.Market size and forecast, by Sales channel

7.4.5.2.Japan

7.4.5.2.1.Market size and forecast, by Type
7.4.5.2.2.Market size and forecast, by Form
7.4.5.2.3.Market size and forecast, by Sales channel

7.4.5.3.India

7.4.5.3.1.Market size and forecast, by Type
7.4.5.3.2.Market size and forecast, by Form
7.4.5.3.3.Market size and forecast, by Sales channel

7.4.5.4.Australia

7.4.5.4.1.Market size and forecast, by Type
7.4.5.4.2.Market size and forecast, by Form
7.4.5.4.3.Market size and forecast, by Sales channel

7.4.5.5.South Korea

7.4.5.5.1.Market size and forecast, by Type
7.4.5.5.2.Market size and forecast, by Form
7.4.5.5.3.Market size and forecast, by Sales channel

7.4.5.6.Rest of Asia-Pacific

7.4.5.6.1.Market size and forecast, by Type
7.4.5.6.2.Market size and forecast, by Form
7.4.5.6.3.Market size and forecast, by Sales channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by Type
7.5.3.Market size and forecast, by Form
7.5.4.Market size and forecast, by Sales channel
7.5.5.Market analysis, by country

7.5.5.1.Brazil

7.5.5.1.1.Market size and forecast, by Type
7.5.5.1.2.Market size and forecast, by Form
7.5.5.1.3.Market size and forecast, by Sales channel

7.5.5.2.Argentina

7.5.5.2.1.Market size and forecast, by Type
7.5.5.2.2.Market size and forecast, by Form
7.5.5.2.3.Market size and forecast, by Sales channel

7.5.5.3.Saudi Arabia

7.5.5.3.1.Market size and forecast, by Type
7.5.5.3.2.Market size and forecast, by Form
7.5.5.3.3.Market size and forecast, by Sales channel

7.5.5.4.United Arab Emirates

7.5.5.4.1.Market size and forecast, by Type
7.5.5.4.2.Market size and forecast, by Form
7.5.5.4.3.Market size and forecast, by Sales channel

7.5.5.5.South Africa

7.5.5.5.1.Market size and forecast, by Type
7.5.5.5.2.Market size and forecast, by Form
7.5.5.5.3.Market size and forecast, by Sales channel

7.5.5.6.Rest of LAMEA

7.5.5.6.1.Market size and forecast, by Type
7.5.5.6.2.Market size and forecast, by Form
7.5.5.6.3.Market size and forecast, by Sales channel

CHAPTER 8:COMPETITION LANDSCAPE

8.1.Overview
8.2.Competitive dashboard
8.3.Competitive heat map
8.4.Product mapping
8.5.Top winning strategies
8.6.Key developments

8.6.1.Acquisition
8.6.2.Business Expansion
8.6.3.Joint Venture
8.6.4.Partnership
8.6.5.Product Launch

8.7.Top Player Positioning

CHAPTER 9:COMPANY PROFILES

9.1.ARCHER DANIELS MIDLAND COMPANY

9.1.1.Company overview
9.1.2.Key executive
9.1.3.Company snapshot
9.1.4.Operating business segments
9.1.5.Product portfolio
9.1.6.R&D expenditure
9.1.7.Business performance
9.1.8.Key strategic moves and developments

9.2.BASF SE

9.2.1.Company overview
9.2.2.Key Executives
9.2.3.Company snapshot
9.2.4.Operating business segments
9.2.5.Product portfolio
9.2.6.Business performance
9.2.7.Key strategic moves and developments

9.3.CARGILL, INC.

9.3.1.Company overview
9.3.2.Key executives
9.3.3.Company snapshot
9.3.4.Operating business segments
9.3.5.Product portfolio
9.3.6.Business performance
9.3.7.Key strategic moves and developments

9.4.DANONE

9.4.1.Company overview
9.4.2.Key Executives
9.4.3.Company snapshot
9.4.4.Operating business segments
9.4.5.Product portfolio
9.4.6.Business performance
9.4.7.Key strategic moves and developments

9.5.DUPONT DE NEMOURS, INC.

9.5.1.Company overview
9.5.2.Key Executives
9.5.3.Company snapshot
9.5.4.Operating business segments
9.5.5.Product portfolio
9.5.6.R&D Expenditure
9.5.7.Business performance

9.6.GENERAL MILLS INC.

9.6.1.Company overview
9.6.2.Key executives
9.6.3.Company snapshot
9.6.4.Operating business segments
9.6.5.Product portfolio
9.6.6.R&D expenditure
9.6.7.Business performance
9.6.8.Key strategic moves and developments

9.7.KONINKLIJKE DSM N.V.

9.7.1.Company overview
9.7.2.Key executive
9.7.3.Company snapshot
9.7.4.Operating business segments
9.7.5.Product portfolio
9.7.6.R&D expenditure (Continued and discontinued operations)
9.7.7.Business performance (Continued and discontinued operations)

9.8.NESTLE S.A.

9.8.1.Company overview
9.8.2.Key Executives
9.8.3.Company snapshot
9.8.4.Operating business segments
9.8.5.Product portfolio
9.8.6.R&D Expenditure
9.8.7.Business performance
9.8.8.Key strategic moves and developments

9.9.PEPSICO, INC.

9.9.1.Company overview
9.9.2.Key Executives
9.9.3.Company snapshot
9.9.4.Operating business segments
9.9.5.Product portfolio
9.9.6.R&D Expenditure
9.9.7.Business performance
9.9.8.Key strategic moves and developments

9.10.YAKULT HONSHA CO., LTD.

9.10.1.Company overview
9.10.2.Key Executives
9.10.3.Company snapshot
9.10.4.Operating business segments
9.10.5.Product portfolio
9.10.6.R&D Expenditure
9.10.7.Business performance
9.10.8.Key strategic moves and developments

LIST OF TABLES

TABLE 01.NUTRACEUTICALS MARKET, BY TYPE, 2020–2030 ($ MILLION)
TABLE 02.FUNCTIONAL BEVERAGES NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 03.FUNCTIONAL FOOD NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 04.DIETARY SUPPLEMENTS NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 05.NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 06.CAPSULE AND TABLETS NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 07.LIQUID NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 08.POWDER NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 09.OTHERS NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 10.NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 11.NUTRACEUTICALS MARKET SALES VIA HYPERMARKET/SUPERMARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 12.NUTRACEUTICALS MARKET SALES VIA SPECIALTY STORES, BY REGION, 2020–2030 ($ MILLION)
TABLE 13.NUTRACEUTICALS MARKET SALES VIA PHARMACY, BY REGION, 2020–2030 ($ MILLION)
TABLE 14.NUTRACEUTICALS MARKET SALES VIA ONLINE CHANNELS, BY REGION, 2020–2030 ($ MILLION)
TABLE 15.NUTRACEUTICALS MARKET, BY REGION, 2020–2030 ($ MILLION)
TABLE 16.NORTH AMERICA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 17.NORTH AMERICA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 18.NORTH AMERICA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 19.NORTH AMERICA NUTRACEUTICALS MARKET VALUE, BY COUNTRY, 2020–2030 ($ MILLION)
TABLE 20.U.S. NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 21.U.S. NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 22.U.S. NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 23.CANADA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 24.CANADA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 25.CANADA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 26.MEXICO NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 27.MEXICO NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 28.MEXICO NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 29.EUROPE NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 30.EUROPE NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 31.EUROPE NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 32.EUROPE NUTRACEUTICALS MARKET VALUE, BY COUNTRY, 2020–2030 ($ MILLION)
TABLE 33.UK NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 34.UK NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 35.UK NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 36.GERMANY NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 37.GERMANY NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 38.GERMANY NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 39.ITALY NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 40.ITALY NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 41.ITALY NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 42.FRANCE NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 43.FRANCE NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 44.FRANCE NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 45.SPAIN NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 46.SPAIN NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 47.SPAIN NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 48.REST OF EUROPE NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 49.REST OF EUROPE NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 50.REST OF EUROPE NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 51.ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 52.ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 53.ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 54.ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY COUNTRY, 2020–2030 ($ MILLION)
TABLE 55.CHINA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 56.CHINA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 57.CHINA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 58.JAPAN NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 59.JAPAN NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 60.JAPAN NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 61.INDIA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 62.INDIA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 63.INDIA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 64.AUSTRALIA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 65.AUSTRALIA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 66.AUSTRALIA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 67.SOUTH KOREA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 68.SOUTH KOREA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 69.SOUTH KOREA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 70.REST OF ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 71.REST OF ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 72.REST OF ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 73.LAMEA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 74.LAMEA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 75.LAMEA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 76.LAMEA NUTRACEUTICALS MARKET VALUE, BY COUNTRY, 2020–2030 ($ MILLION)
TABLE 77.BRAZIL NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 78.BRAZIL NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 79.BRAZIL NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 80.ARGENTINA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 81.ARGENTINA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 82.ARGENTINA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 83.SAUDI ARABIA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 84.SAUDI ARABIA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 85.SAUDI ARABIA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 86.UNITED ARAB EMIRATES NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 87.UNITED ARAB EMIRATES NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 88.UNITED ARAB EMIRATES NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 89.SOUTH AFRICA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 90.SOUTH AFRICA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 91.SOUTH AFRICA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 92.REST OF LAMEA NUTRACEUTICALS MARKET VALUE, BY TYPE, 2020–2030 ($ MILLION)
TABLE 93.REST OF LAMEA NUTRACEUTICALS MARKET VALUE, BY FORM, 2020–2030 ($ MILLION)
TABLE 94.REST OF LAMEA NUTRACEUTICALS MARKET VALUE, BY SALES CHANNEL, 2020–2030 ($ MILLION)
TABLE 95.ARCHER DANIELS MIDLAND COMPANY: KEY EXECUTIVE
TABLE 96.ARCHER DANIELS MIDLAND COMPANY: COMPANY SNAPSHOT
TABLE 97.ARCHER DANIELS MIDLAND COMPANY: OPERATING SEGMENTS
TABLE 98.ARCHER DANIELS MIDLAND COMPANY: PRODUCT PORTFOLIO
TABLE 99.ARCHER DANIELS MIDLAND COMPANY: R&D EXPENDITURE, 2018-2020 ($MILLION)
TABLE 100.ARCHER DANIELS MIDLAND COMPANY: NET SALES, 2018-2020 ($MILLION)
TABLE 101.BASF SE: KEY EXECUTIVES
TABLE 102.BASF SE: COMPANY SNAPSHOT
TABLE 103.BASF SE: OPERATING SEGMENTS
TABLE 104.BASF SE: PRODUCT PORTFOLIO
TABLE 105.BASF SE: NET SALES, 2018-2020 ($MILLION)
TABLE 106.CARGILL, INC.: KEY EXECUTIVES
TABLE 107.CARGILL, INC.: COMPANY SNAPSHOT
TABLE 108.CARGILL, INC.: OPERATING SEGMENTS
TABLE 109.CARGILL, INC..: PRODUCT PORTFOLIO
TABLE 110.CARGILL, INC.: NET SALES, 2020-2021 ($MILLION)
TABLE 111.DANONE: KEY EXECUTIVES
TABLE 112.DANONE: COMPANY SNAPSHOT
TABLE 113.DANONE: OPERATING SEGMENTS
TABLE 114.DANONE: PRODUCT PORTFOLIO
TABLE 115.DANONE: NET SALES, 2018–2020 ($MILLION)
TABLE 116.DUPONT DE NEMOURS, INC.: KEY EXECUTIVES
TABLE 117.DUPONT DE NEMOURS, INC.: COMPANY SNAPSHOT
TABLE 118.DUPONT DE NEMOURS, INC.: OPERATING SEGMENTS
TABLE 119.DUPONT DE NEMOURS, INC.: PRODUCT PORTFOLIO
TABLE 120.DUPONT DE NEMOURS, INC.: R&D EXPENDITURE, 2018–2020 ($MILLION)
TABLE 121.DUPONT DE NEMOURS, INC.: NET SALES, 2018–2020 ($MILLION)
TABLE 122.GENERAL MILLS INC.: KEY EXECUTIVES
TABLE 123.GENERAL MILLS INC.: COMPANY SNAPSHOT
TABLE 124.GENERAL MILLS INC.: OPERATING SEGMENTS
TABLE 125.GENERAL MILLS INC.: PRODUCT PORTFOLIO
TABLE 126.GENERAL MILLS INC.: R&D EXPENDITURE, 2018–2020 ($MILLION)
TABLE 127.GENERAL MILLS INC.: NET SALES, 2018–2020 ($MILLION)
TABLE 128.KONINKLIJKE DSM N.V.: KEY EXECUTIVE
TABLE 129.KONINKLIJKE DSM N.V.: COMPANY SNAPSHOT
TABLE 130.KONINKLIJKE DSM N.V.: OPERATING SEGMENTS
TABLE 131.KONINKLIJKE DSM N.V.: PRODUCT PORTFOLIO
TABLE 132.KONINKLIJKE DSM N.V.: R&D EXPENDITURE, 2018-2020 ($MILLION)
TABLE 133.KONINKLIJKE DSM N.V.: NET SALES, 2018-2020 ($MILLION)
TABLE 134.NESTLE S.A.: KEY EXECUTIVES
TABLE 135.NESTLE S.A.: COMPANY SNAPSHOT
TABLE 136.NESTLE S.A.: OPERATING SEGMENTS
TABLE 137.NESTLE S.A.: PRODUCT PORTFOLIO
TABLE 138.NESTLE S.A.: R&D EXPENDITURE, 2018–2020 ($MILLION)
TABLE 139.NESTLE S.A.: NET SALES, 2018–2020 ($MILLION)
TABLE 140.PEPSICO, INC.: KEY EXECUTIVES
TABLE 141.PEPSICO, INC.: COMPANY SNAPSHOT
TABLE 142.PEPSICO, INC.: OPERATING SEGMENTS
TABLE 143.PEPSICO, INC.: PRODUCT PORTFOLIO
TABLE 144.PEPSICO, INC.: R&D EXPENDITURE, 2018–2020  ($MILLION)
TABLE 145.PEPSICO, INC.: NET SALES, 2018–2020 ($MILLION)
TABLE 146.YAKULT HONSHA CO., LTD.: KEY EXECUTIVES
TABLE 147.YAKULT HONSHA CO., LTD.: COMPANY SNAPSHOT
TABLE 148.YAKULT HONSHA CO., LTD.: OPERATING SEGMENTS
TABLE 149.YAKULT HONSHA CO., LTD.: PRODUCT PORTFOLIO
TABLE 150.YAKULT HONSHA CO., LTD.: R&D EXPENDITURE, 2018–2020 ($MILLION)
TABLE 151.YAKULT HONSHA CO., LTD.: NET SALES, 2018–2020 ($MILLION)

LIST OF FIGURES

FIGURE 01.KEY MARKET SEGMENTS
FIGURE 02.EXECUTIVE SUMMARY
FIGURE 03.TOP IMPACTING FACTORS
FIGURE 04.TOP INVESTMENT POCKETS
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.HIGH BARGAINING POWER OF BUYERS
FIGURE 07.LOW THREAT OF SUBSTITUTION
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.HIGH INTENSITY OF COMPETITIVE RIVALRY
FIGURE 10.NUTRACEUTICALS MARKET, BY TYPE, 2020 (%)
FIGURE 11.COMPARATIVE VALUE SHARE ANALYSIS OF FUNCTIONAL BEVERAGES NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE VALUE SHARE ANALYSIS OF FUNCTIONAL FOOD NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13.COMPARATIVE VALUE SHARE ANALYSIS OF DIETARY SUPPLEMENTS NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.NUTRACEUTICALS MARKET, BY FORM, 2020 (%)
FIGURE 15.COMPARATIVE VALUE SHARE ANALYSIS OF CAPSULE AND TABLETS NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE VALUE SHARE ANALYSIS OF LIQUID NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE VALUE SHARE ANALYSIS OF POWDER NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE VALUE SHARE ANALYSIS OF OTHERS NUTRACEUTICALS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.NUTRACEUTICALS MARKET, BY SALES CHANNEL, 2020 (%)
FIGURE 20.COMPARATIVE VALUE SHARE ANALYSIS OF NUTRACEUTICALS SALES VIA HYPERMARKET/SUPERMARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.COMPARATIVE VALUE SHARE ANALYSIS OF NUTRACEUTICALS SALES VIA SPECIALTY STORES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.COMPARATIVE VALUE SHARE ANALYSIS OF NUTRACEUTICALS SALES VIA PHARMACY, BY COUNTRY, 2020 & 2030 (%)
FIGURE 23.COMPARATIVE VALUE SHARE ANALYSIS OF NUTRACEUTICALS SALES VIA ONLINE CHANNELS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.NUTRACEUTICALS MARKET, BY REGION 2020 (%)
FIGURE 25.U.S. NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 26.CANADA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 27.MEXICO NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 28.UK NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 29.GERMANY NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 30.ITALY NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 31.FRANCE NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 32.SPAIN NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 33.REST OF EUROPE NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 34.CHINA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 35.JAPAN NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 36.INDIA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 37.AUSTRALIA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 38.SOUTH KOREA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 39.REST OF ASIA-PACIFIC NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 40.BRAZIL NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 41.ARGENTINA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 42.SAUDI ARABIA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 43.UNITED ARAB EMIRATES NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 44.SOUTH AFRICA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 45.REST OF LAMEA NUTRACEUTICALS MARKET VALUE, 2020-2030 ($ MILLION)
FIGURE 46.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 48.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 49.TOP WINNING STRATEGIES, BY YEAR, 2018–2021*
FIGURE 50.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021* (%)
FIGURE 51.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021*
FIGURE 52.PLAYER POSITIONING OF TOP 10 KEY PLAYERS
FIGURE 53.ARCHER DANIELS MIDLAND COMPANY: R&D EXPENDITURE, 2018-2020 ($MILLION)
FIGURE 54.ARCHER DANIELS MIDLAND COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 55.ARCHER DANIELS MIDLAND COMPANY: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 56.ARCHER DANIELS MIDLAND COMPANY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 57.BASF SE: NET SALES, 2018-2020 ($MILLION)
FIGURE 58.BASF SE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 59.BASF SE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 60.CARGILL, INC..: NET SALES, 2020-2021 ($MILLION)
FIGURE 61.DANONE: NET SALES, 2018–2020 ($MILLION)
FIGURE 62.DANONE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 63.DUPONT DE NEMOURS, INC.: R&D EXPENDITURE, 2018–2020 ($MILLION)
FIGURE 64.DUPONT DE NEMOURS, INC.: NET SALES, 2018–2020 ($MILLION)
FIGURE 65.DUPONT DE NEMOURS, INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 66.DUPONT DE NEMOURS, INC.: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 67.GENERAL MILLS INC.: R&D EXPENDITURE, 2018–2020 ($MILLION)
FIGURE 68.GENERAL MILLS INC.: NET SALES, 2018–2020 ($MILLION)
FIGURE 69.GENERAL MILLS INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 70.GENERAL MILLS INC.: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 71.KONINKLIJKE DSM N.V.: R&D EXPENDITURE, 2018-2020 ($MILLION)
FIGURE 72.KONINKLIJKE DSM N.V.: NET SALES, 2018-2020 ($MILLION)
FIGURE 73.KONINKLIJKE DSM N.V.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 74.KONINKLIJKE DSM N.V.: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 75.NESTLE S.A.: R&D EXPENDITURE, 2018–2020 ($MILLION)
FIGURE 76.NESTLE S.A.: NET SALES, 2018–2020 ($MILLION)
FIGURE 77.NESTLE S.A.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 78.NESTLE S.A.: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 79.PEPSICO, INC.: R&D EXPENDITURE, 2018–2020 ($MILLION)
FIGURE 80.PEPSICO, INC.: NET SALES, 2018–2020 ($MILLION)
FIGURE 81.PEPSICO, INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 82.YAKULT HONSHA CO., LTD.: R&D EXPENDITURE, 2018–2020 ($MILLION)
FIGURE 83.YAKULT HONSHA CO., LTD.: NET SALES, 2018–2020 ($MILLION)
FIGURE 84.YAKULT HONSHA CO., LTD.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 85.YAKULT HONSHA CO., LTD.: REVENUE SHARE BY REGION, 2020 (%)

The 21st century has seen a rapid increase in the business and severity of the lifestyle led by the people, especially the office going people that make up the majority of the world population. This has led to numerous health problems and complications as people cannot devote enough time towards healthy eating habits and exercise. However, there has been an increase in the awareness regarding such problems, and consumers are now adopting healthy practices like exercising and adoption of nutraceuticals.

Depending on the strength and the potency of the ingredients in the nutraceutical products, they can be consumed either daily or a few times a week. Most of the nutraceutical products available in the market are focused one or two aspects of health, such as vitamins and minerals or proteins and amino acids. Some nutraceutical can be paired with other kinds of healthy foods, like addition of powdered or liquid nutraceutical products in juices or smoothies. It can also enhance the taste of these foods as most of the nutraceutical products in the market are available in a myriad of flavors. As these nutraceutical products are made from food material, they are considered safe for consumption and are not classified under pharmaceutical products. Most of the countries in the world do not regulate nutraceuticals heavily, so they are available easily.

Increasing number of consumers that are adopting organic diets are propelling the engaged stakeholders in the nutraceutical market to focus on using organic and herbal ingredients for the production of their nutraceuticals, especially in the Asia-Pacific region which has a culture of herbal and Ayurvedic medicine. Furthermore, there is also an increase in demand for vegan nutraceutical products as the trend of veganism is also on the rise. Rapid increase in sales of nutraceuticals via online channels in also expected in the future.